Oral Weight Loss Drug Orforglipron Effective Across Menopausal Stages

New Phase 3 trial results for orforglipron, an oral GLP-1 receptor agonist, confirm its ability to deliver significant weight loss in women across all stages of menopause. The drug, which received FDA approval earlier this year for obesity and overweight adults, demonstrated substantial weight reductions in both ATTAIN-1 and ATTAIN-2 trials. Its convenient once-daily oral administration without food or water restrictions is a key feature.